Chronic Use of Immunosuppressive Drugs Does Not Worsen COVID-19 Outcomes
Study authors conducted a retrospective cohort study to assess whether chronic immunosuppression worsens outcomes for patients hospitalized with COVID-19.
Study authors conducted a retrospective cohort study to assess whether chronic immunosuppression worsens outcomes for patients hospitalized with COVID-19.
Study authors compared oral moxifloxacin with combined intravenous ertapenem followed by oral levofloxacin in the managed of uncomplicated acute appendicitis.
This study’s goal was to study the effect of fatty liver on the incidence of cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in patients with chronic hepatitis B.
This retrospective study aims to shed light on the relationship between splenic infarction and infection.
Innovations such as accurate, rapid, point-of-care tests are needed to regain traction against increasing rates of sexually transmitted infections.
Investigators explored the implications of updated vaccination strategies for typhoid fever targeting younger at-risk children in the United States.
Retrospective analysis was conducted to assess the presence of A faecalis infection, extensively drug-resistant A faecalis infection, and the susceptibility of commonly used antibiotics for the treatment of A faecalis and XDR A faecalis.
Investigators assessed whether a daily service of infectious disease consultation was more effective than weekly consultation to reduce antibiotic use without worsening clinical outcomes.
Investigators determined whether fluvoxamine prevents clinical deterioration and decreases severity of disease in patients with mild COVID-19 illness.
AstraZeneca assessed the immunogenicity, safety, and efficacy of their novel chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 nCoV-19.